AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00741260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib orally once daily continually
Study NCT01594723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg LY2784544
Description: Administered orally
Study NCT03531073 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: This study is observational and patients will receive treatment for their psoriatic arthritis as clinically indicated. As per standard practice in this observational cohort, patients are most likely to be treated with methotrexate as the most common first line therapy in PsA. This cohort is the basis of a TWiCs (Trials Within Cohorts) study design and interventional studies will be nested within this in future. Whilst the cohort will receive treatment for their PsA as part of their routine clinical care, this treatment will be decided according to routine care and not protocolised.
Study NCT03617731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)
Study NCT03617731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)
Study NCT03617731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
Study NCT03617731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
Study NCT03617731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.
Study NCT03617731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.
Study NCT03617731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: 10 mg/kg in the vein( i.v) on day 1,8,15, 22, 29 in induction cycle 1 on day 1, 15 and 29 in induction cycle 2 and 3 (Arm IB). 10 mg/kg i.v. on day 1,8, 15 and 22 in maintenance cycle 1, 10 mg/kg i.v. on day 1 and 15 in maintenance cycle 2 and 3, 10 mg/kg i.v. on day 1 in maintenance cycle 4 - 39 (Arm IIB)
Study NCT04167358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat
Description: All participants will receive linerixibat.
Study NCT00741260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine orally on days 1-14 of each 21 day cycle
Study NCT02945839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preventative Medication (PM)
Description: Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.
Study NCT02945839 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: General Education Class consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
Study NCT02945839 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PMR (progressive muscle relaxation therapy)
Description: Technique for learning to monitor and control the state of muscular tension
Study NCT05292573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: During the intervention period, metformin is given 500 mg tablet b.i.d. Those who stopped taking metformin will remain in the study not counting as protocol violation.
Study NCT02506491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise
Description: 2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
Study NCT02506491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscular exercise
Description: 2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
Study NCT02506491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: No exercise
Study NCT02995473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP000888
Description: 270 µg/g topical (BID) for 24 weeks
Study NCT02995473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical (BID) for 24 weeks
Study NCT03217175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bihormonal Bionic Pancreas
Description: The glucagon pump will be filled with glucagon during the exercise visit
Study NCT03217175 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Only Bionic Pancreas
Description: The glucagon pump will be filled with placebo during the exercise visit, and the bionic pancreas will operate in an insulin only mode.
Study NCT01900405 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Study NCT01510028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human arylsulfatase A
Description: 6 patients treated with HGT-1110 EOW by IT injection
Study NCT00918840 — intervention group
Intervention type: BIOLOGICAL
Intervention: DermaVir
Description: DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells
Study NCT00918840 — intervention group
Intervention type: BIOLOGICAL
Intervention: Placebo
Description: Dextrose/glucose solution
Study NCT03217175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon will be given according to the algorithm in the bihormonal bionic pancreas
Study NCT03217175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
Study NCT03102372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Study NCT03102372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: walking program
Study NCT03102372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking program
Study NCT03102372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Very Low Calorie Diet
Study NCT03102372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet
Study NCT04454268 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cyst extirpation
Description: complete removal of the cyst without rupture
Study NCT03006926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: 4 mg capsules
Study NCT03598621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 0.5 mg/mL
Description: A single dose will be administered subcutaneously (s.c.; under the skin) in the morning after an overnight fast of at least 8 hours.
Study NCT03006926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (200 mg)
Description: 30-minute intravenous infusion
Study NCT03892434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab and dexamethasone implant Injection
Description: Bevacizumab 1.25mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion, and Dexamethasone 0.75mg implant is injected using injector.
Study NCT03892434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal dexamethasone implant
Description: Dexamethasone implant insertion using approved kit
Study NCT01793090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epi-743
Description: EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.
Study NCT01793090 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Placebo will be administered in the same formulation as the active comparator
Study NCT01698177 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Seasonal inactivated trivalent vaccine
Study NCT00120510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime
Study NCT00120510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime
Study NCT00120510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/Zidovudine
Description: Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
Study NCT00120510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine/Zidovudine
Description: Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
Study NCT01122888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Given IV
Study NCT01122888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Observation
Description: Patients undergo a 2-week rest period
Study NCT00918840 — intervention group
Intervention type: DRUG
Intervention: HAART
Description: Three or more antiretroviral drugs that can fully suppress HIV RNA
Study NCT00093873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-angiogenesis
Description: Anti-angiogenesis
Study NCT00093873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: Anti-angiogenesis
Study NCT03482700 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention Arm
Description: The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
Study NCT03482700 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Arm
Description: Usual standard of care
Study NCT01147263 — intervention group
Intervention type: OTHER
Intervention: Evaluation of autonomic parameters
Description: Physical examination, ECG, Loop recorder, Heart rate variability evaluation
Study NCT03598621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 1.0 mg/mL
Description: A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
Study NCT03598621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 1.34 mg/mL
Description: A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
Study NCT03598621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 2.0 mg/mL
Description: A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
Study NCT03598621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DV3372, 0.5 mg/mL
Description: DV3372 device will be used for administration of semaglutide 0.5 mg/mL.
Study NCT03598621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DV3372, 1.0 mg/mL
Description: DV3372 device will be used for administration of semaglutide 1.0 mg/mL.
Study NCT03598621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDS290
Description: PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.
Study NCT03598621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoPen®4
Description: NovoPen®4 will be used for administration of semaglutide 2.0 mg/mL.
Study NCT03628677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
Study NCT01122888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01122888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01160263 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
Description: 123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter.
Study NCT04254445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized training video
Description: Using a few demographic and medical details of the patients, provided by the medical staff, the video generator will create a 2-minute personalized custom video, suitable to the age, gender, language, and medical condition of the patients. No identifying information will be used, to protect patient's privacy.
Study NCT04021576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preventative training program
Description: complementary training of leg-, hip- and core-strength/stability
Study NCT02230839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete a progressive 6-month exercise training program, 4-5 days per week, 45 min per session (180 min per week), consisting mostly of walking (both outside and on an indoor treadmill) but with the option to include stationary cycling, elliptical and rowing machines, similar to what we have utilized previously to elicit significant improvements in insulin sensitivity in both middle-age and older adults (52-55). Beginning at week 8, these subjects will also perform 2 non-consecutive resistance exercise sessions per week, 30 min per session, focused on major muscle groups using resistance machines (total days of exercise will still be 4 to 5).
Study NCT02230839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Restriction-Induced Weight Loss
Description: The goal of the weight loss intervention will be to produce a weight loss of 10% body weight. A reduction of 500-1000 kcal/day - based on baseline weight -and low fat (\<30% of calories from fat) diet will be used as part of the weight loss intervention.
Study NCT01316380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
Study NCT01316380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium 2.5 mcg
Description: To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
Study NCT01316380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium 5 mcg
Description: To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
Study NCT03272971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio-frequency Ablation
Description: The intervention consists of a bronchoscopic approach to ablate lung tumors with radiofrequency.
Study NCT00003838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-cell replete PBPC allograft
Description: Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days with or without ATG followed by a PBPC graft targeted to deliver >5x10\^6 CD34+ cells/kg.
Study NCT00003838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IV MTX on days +1, +3, and +6 will be given
Study NCT03903848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Single session of treadmill walking and resistance exercise
Study NCT00003838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: CSA will be given beginning on day -4 for graft versus host disease prophylaxis. Participants with mixed T-cell chimerism on day 30 will begin a CSA taper. Participants with 100% donor T-cell chimerism by day 30 will be tapered off CSA from days 60 through 100 (25% reduction in dose every 10 days-off by day 100). CSA will not be tapered in any subjects with grade > II acute GVHD regardless of chimerism results. In addition, participants with evidence of disease progression without grade > II GVHD will have CSA discontinued regardless of chimerism results.
Study NCT00003838 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
Study NCT00879047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks
Study NCT00879047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol placebo
Description: Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
Study NCT03454724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System
Description: MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
Study NCT03454724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System
Description: MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
Study NCT03454724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience EES Everolimus Eluting Coronary Stent System
Description: Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
Study NCT03454724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience EES Everolimus Eluting Coronary Stent System
Description: Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
Study NCT04409730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photographic Posture Analysis
Description: Postural evaluation was done using the photographic method. All measurements were made by two researchers experienced in postural analysis evaluation. Canon camera and national geographic tripod with double spirit level were used for evaluation. The camera was placed on a 115 cm high tripod, 1.5 m away from the subjects. Spirit levels have been adjusted so that the tripod is completely flat on the ground. The tripod was taped to the floor to maintain the same distance between the camera and the participants. Six photographs of each child whose feet on the ground, in a free-sitting position, 3 from the front and 3 sides were taken by the researchers.
Study NCT03900663 — intervention group
Intervention type: DEVICE
Intervention: Anthropometric measures
Description: Measure body weight , height , chest circumference , mid upper arm circumference,skin fold thickness , head circumference
Study NCT04228445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%
Description: Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
Study NCT04228445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline spray
Description: Placebo
Study NCT04228445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray
Description: Placebo
Study NCT02164604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of 0.03ml ranibizumab